Then, in 2010, Pfizer and Medivation announced that Dimebon failed to meet its primary and secondary goals in a phase 3 trial studying the drug's use by itself against placebo among mild-to-moderate Alzheimer's patients.
"Phase III trial results for secondary indications of marketed drugs that fail to achieve approval will also be posted, " Lilly stated in its press release.
In the second phase, UNESCO reviewed and printed 9 million copies of primary and secondary school textbooks, which benefited 6 million students throughout Iraq for the academic year 2005-2006.